Loading stock data…
Acumen Pharmaceuticals (ABOS)
$3.16-0.02 (-0.63%)
After Hours$3.21+0.05 (+1.58%)· Last close Sep 8
Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer's disease.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Acumen Pharmaceuticals, Inc. in the Healthcare sector is trading at $3.16 with a market capitalization of $170M. Wall Street consensus targets $7.40 (5 analysts), implying a +134.2% move over the next 12 months. The stock is currently near its 52-week high of $3.60, remaining 29.0% above its 200-day moving average. On fundamentals, Piotroski 2/9 flags weak fundamentals, Altman Z in the distress zone. The Whystock Score of 70/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +134.2% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$21.15M↑ | -$25.20M↑ | -$26.51M↑ | -$41.75M↓ | -$30.37M |
| Net Income | -$20.74M↑ | -$25.14M↑ | -$26.45M↑ | -$40.95M↓ | -$28.80M |
Peer Comparison
JNJUNHPFE
Fundamentals
Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer's disease. It focuses on advancing a targeted immunotherapy drug candidate, sabirnetug (ACU193), which is in its Phas...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$170.10M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-129.49%
Volume
Today's trading volume
357,678
Recent News
Acumen Pharmaceuticals Inc (ABOS) (Q2 2026) Earnings Call Highlights: Advancing Sabirnetug ...
Acumen Pharmaceuticals Inc (ABOS) reports strong progress on its lead Alzheimer's candidate and next-generation pipeline, with cash runway into early 2027.
Acumen Pharmaceuticals, Inc. Q2 2026 Earnings Call Summary
Moby summary of Acumen Pharmaceuticals, Inc.'s Q2 2026 earnings call
Acumen Pharmaceuticals Q2 Earnings Call Highlights
Acumen Pharmaceuticals (NASDAQ:ABOS) said it remains on track to report top-line results late in 2026 from its Phase II ALTITUDE-AD study of sabirnetug, an investigational antibody designed to selectively target synaptotoxic amyloid-beta oligomers in early Alzheimer’s disease. Chief Executive Offic
VERAXA Biotech Shows Regulatory Progress on Cancer Therapy Platform
By Daniella Parra VERAXA Biotech said it received positive scientific advice from Germany’s Paul-Ehrlich-Institute supporting a preclinical development plan for its experimental BiTAC-TCE cancer therapy platform. The feedback provides greater regulatory clarity and reduces some early-stage development risk as the company advances its lead candidate toward clinical trials, it said. READ MORE The Cancer […] The post VERAXA Biotech Shows Regulatory Progress on Cancer Therapy Platform appeared first
Slate Medicines Appoints Mark W. Hahn to Board of Directors
By Daniella Parra Slate Medicines, a private biotech company developing new treatments for migraine and other headache disorders, has appointed Mark W. Hahn to its Board of Directors, they said. The company said Hahn brings more than 25 years of life sciences leadership experience, including serving as CFO of Verona Pharma, where he helped guide […] The post Slate Medicines Appoints Mark W. Hahn to Board of Directors appeared first on ExecEdge.